Physician profile
Kent G Mcdaniel
NPI 1871640789
$2,136,452.52
in general payments reported to CMS, 2019-2025
11 companies · $399K in 2025
The $399K reported for 2025 was more than what 99% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $281K · 2020: $57K · 2021: $210K · 2022: $376K · 2023: $410K · 2024: $405K · 2025: $399K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1.1M · Travel and Lodging: $84K · Consulting Fee: $30K · Food and Beverage: $21K · Education: $27.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,077,764.85 |
| Travel and Lodging | $84,033.59 |
| Consulting Fee | $30,360.00 |
| Food and Beverage | $21,093.05 |
| Education | $27.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $587,704.67 | 2019-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Neurocrine Biosciences, INC. | $408,318.70 | 2019-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $367,008.52 | 2019-2025 | Invega Sustenna, Invega Trinza |
| Alkermes, INC. | $357,679.30 | 2019-2023 | Lybalvi, Aristada, Aristada Initio |
| Teva Pharmaceuticals USA, INC. | $229,575.40 | 2023-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $160,301.34 | 2021-2025 | Caplyta |
| E.R. Squibb & Sons, L.L.C. | $18,387.34 | 2024-2025 | Cobenfy |
| Sunovion Pharmaceuticals INC. | $7,208.36 | 2019-2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $131.47 | 2019-2021 | |
| Gilead Sciences, INC. | $123.50 | 2023 | Epclusa |
| Abbvie INC. | $13.92 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kent Mcdaniel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.